Every 10-Q that Kewaunee Scientific Corp (KEQU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KEQU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KEQU filings page.
Kewaunee Scientific Corporation (KEQU) reported weaker first-quarter FY2027 results for the three months ended July 31, 2026, as net sales declined to $66.3 million from $71.1 million a year earlier, reflecting softer demand in the domestic laboratory construction market and India.
Net earnings attributable to Kewaunee fell to $1.7 million from $3.1 million, and diluted EPS decreased to $0.58 from $1.04, driven mainly by lower sales and a higher effective tax rate, partly offset by slightly improved gross margin of 29.6% versus 29.4% and reduced interest expense.
Order backlog was $169.0 million at July 31, 2026, down from $205.0 million a year earlier but modestly above $165.9 million at April 30, 2026. Operating cash flow was $2.0 million versus $5.8 million in the prior-year quarter, while term loan balances declined to $18.8 million and cash, cash equivalents and restricted cash totaled $10.3 million. The company repurchased 14,290 shares under its ongoing buyback program and ended the quarter with 2,895,347 shares outstanding and full $20.0 million availability on its revolving credit facility.
Kewaunee Scientific Corporation reported quarterly net sales of $69,399,000, slightly above $67,167,000 a year ago, and nine‑month net sales of $210,599,000 versus $163,324,000, reflecting growth helped by the Nu Aire acquisition. Nine‑month gross profit was $59,195,000, with gross margin improving to 28.1% of sales from 27.4%.
Net earnings attributable to Kewaunee Scientific Corporation for the nine months were $6,230,000, down from $6,555,000, with diluted earnings per share of $2.09 compared to $2.20. Order backlog was $183.2 million at January 31, 2026, below $221.6 million a year earlier and $214.6 million at April 30, 2025.
Operating activities generated $13,173,000 of cash, up from $5,376,000, while cash, cash equivalents and restricted cash decreased to $10,347,000 from $17,164,000. The company refinanced its Nu Aire seller notes, repaying $23,000,000 of principal and related interest, and ended the period with total long‑term debt of $21,333,000 versus $37,685,000, remaining in compliance with loan covenants.
Kewaunee Scientific reported revenue of $70.1M for the quarter ended October 31, 2025, up from $47.8M a year earlier. Net earnings attributable to the company were $2.4M versus $3.0M, with diluted EPS of $0.82 compared with $1.01. For the first six months of fiscal 2026, revenue rose to $141.2M from $96.2M, while net earnings increased to $5.5M and diluted EPS to $1.86 from $1.75.
Gross margin was 28.1% for the quarter versus 29.2% a year ago, and 28.8% year-to-date compared with 27.5%, reflecting the impact of the Nu Aire acquisition and mixed volumes. Nu Aire contributed $19.4M of revenue and $1.1M of net earnings in the quarter, helping drive strong domestic and international sales growth, while operating expenses rose to $15.6M from $9.5M on integration, higher compensation, and international spending.
Order backlog was $192.9M at October 31, 2025, slightly above the prior-year level. Cash, cash equivalents and restricted cash totaled $13.7M, with long-term debt of about $35.3M and a sale-leaseback financing liability of $27.0M. Operating activities provided $1.5M of cash in the first half. After quarter end, Kewaunee amended its PNC loan agreement, added a new $10.0M term loan, and repaid in full the original $23.0M seller notes issued for the Nu Aire acquisition.